Multiple Myeloma

Adam J. Waxman, MD, MS, discusses the role of transplant in patients with multiple myeloma.

Adam J. Waxman, MD, MS, discusses new and upcoming multiple myeloma treatments and how to optimally manage toxicities from these regimens.

Ivan M. Borrello, MD, discusses the most impactful agents that have entered the relapsed/refractory setting of multiple myeloma and details some of the guiding principles of treatment selection.

Edward A. Stadtmauer, MD, discusses the use of selinexor in patients with heavily pretreated, relapsed/refractory multiple myeloma.

The FDA has approved daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Sundar Jagannath, MBBS, discusses the significance the selinexor (Xpovio) approval has for patients with myeloma, the tolerability of the agent, and the management of related adverse events.

Ivan M. Borrello, MD, associate professor of oncology, Johns Hopkins Medicine, discusses the use of selinexor (Xpovio) in the treatment of patients with penta-refractory multiple myeloma.

Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.

Ajai Chari, MD, discusses the use of selinexor in multiple myeloma treatment.

Sarah M. Larson, MD, discusses trials with the potential to shift treatment strategies in the frontline and relapsed/refractory settings of multiple myeloma and remaining research questions in the field.

Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance, the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years.

Samir Parekh, MBBS, discusses using genomics to treat patients with multiple myeloma.

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Adding daratumumab to carfilzomib and dexamethasone improved progression-free survival in patients with relapsed/refractory multiple myeloma, according to topline findings from the phase III CANDOR study.

The all-oral triplet regimen of 60 mg of weekly selinexor plus lenalidomide and dexamethasone appears to be highly active and well-tolerated in patients with relapsed, refractory multiple myeloma, particularly in patients who did not receive prior lenalidomide, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop.

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses interim results of the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Maria-Victoria Mateos, MD, PhD, associate professor of medicine, and director of the Myeloma unit at the University Hospital of Salamanca in Spain, discusses the impact of performance status on the outcomes of patients with multiple myeloma in the phase III ARROW trial.

AMG 701, a half-life–extended anti-BCMA bispecific T-cell engager, showed promising in vitro antimyeloma activity and characteristics suitable for once-weekly dosing in patients with multiple myeloma, according to findings presented at the 17th International Myeloma Workshop.

Shaji Kumar, MD, discusses the addition of the BCL-2 inhibitor venetoclax to the combination of bortezomib and dexamethasone significantly improved progression-free survival, overall response rate, very good partial response, and minimal residual disease negativity rates in the phase III BELLINI trial in relapsed/refractory patients with multiple myeloma.

Melflufen and dexamethasone demonstrated encouraging activity in patients with relapsed/refractory multiple myeloma with and without extramedullary disease, with response rates higher than those observed in prior studies of other agents.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.

The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone for transplant-eligible patients with newly diagnosed multiple myeloma improved the depth of response without affecting stem cell mobilization or hematopoietic reconstitution.

The novel agent iberdomide (formerly CC-220) was safe and showed antitumor activity when combined with dexamethasone in patients with heavily pretreated, relapsed/refractory multiple myeloma, according to findings from a phase Ib/IIa study presented at the 17th International Myeloma Workshop.

Adding the CD38-directed monoclonal antibody isatuximab in combination with pomalidomide and dexamethasone improved progression-free survival in both standard-risk patients with relapsed/refractory multiple myeloma and those with high-risk cytogenetics.

A quadruplet regimen combining the anti-CD38 monoclonal antibody isatuximab with carfilzomib, lenalidomide, and dexamethasone was safe and had a 100% response rate among 10 patients enrolled in the safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial.